An immunological biomarker to predict MTX response in early RA

Annals of the Rheumatic Diseases

Volumn 73, Issue 11, 2014, Pages 2047-2053

  Ponchel, Frederique ^a   Goëb, Vincent ^a,b   Parmar, Rekha ^a   El Sherbiny, Yasser ^a   Boissinot, Marjorie ^a   El Jawhari, Jehan ^a   Burska, Agata ^a   Vital, Edward M ^a   Harrison, Stephanie ^a   Conaghan, Philip G ^a   Hensor, Elizabeth ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG COMBINATION; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PILOT STUDY; PROCEDURES; PROGNOSIS; REMISSION; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84921818106     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203566     Document Type: Article

References (36)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004;43:906-14.
3. Quinn M, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21:154-7.
4. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal-Results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
5. Emery P, Kvien TK, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;71:989-92.
6. Smolen J, Aletaha D, Bijlsma J, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
7. Smolen J, Landewe R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
8. Katchamart W, Johnson S, Lin HJL, et al. Predictors for remission in Rheumatoid Arthritis patients: a systematic review. Arthritis Care Res 2010;62:1128-43.
9. Ponchel F, Vital E, Kingsbury SR, et al. CD4+ T-cell subsets in rheumatoid arthritis. Int J Clin Rheumtol 2012;7:37-53.
10. Ponchel F, Morgan A, Bingham S, et al. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 2002;100:4550-6.
11. Ponchel F, Verburg R, Bingham S, et al. IL-7 deficiency and therapy-induced lymphopenia in Rheumatoid Arthritis. Arthritis Res Ther 2005;7:80-92.
12. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010;69:1636-42.
13. Lawson C, Brown A, Greenstein A, et al. Rheumatoid Arthritis is associated with a deficit in CD4+CD25-high regulatory T-cell in the peripheral blood. Rheumatology 2006;45:1210-17.
14. Conaghan P, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003;48:64-71.
15. Burgoyne C, Field S, Brown AK, et al. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann Rheum Diseases 2008;67:750-7.
16. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of Human CD4+CD25+high Regulatory T Cell Function. J Immunol 2002;169:6210-17.
17. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
18. Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-11.
19. Hyrich KL, Symmons DPM, Watson KD, et al. British Soc Rheumatology. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis-Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
20. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.
21. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008;59:32-41.
22. Emery P, Breedveld F, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
23. Emery P, Kvien T, Combe B, et al. Very early (<4 months) treatment with combination etanercept and methotrexate produces significantly better remission rates: results from the COMET study [abstract]. Ann Rheum Dis 2010;69(Suppl3):S57.
24. Pease CT, Bhakta BB, Devlin J, et al. Does the age of onset of rheumatoid arthritis influence phenotype? a prospective study of outcome and prognostic factors. Rheumatology 1999;38:228-34.
25. Verstappen SMM, Albada-Kuipers GAV, Bijlsma JWJ, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005;64:38-43.
26. Forslind K, Hafstrom I, Ahlmen M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007;66:46-52.
27. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis-The importance of disease duration. Arthritis Rheum 2000;43:22-9.
28. Bukhari MAS, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years-Results from a large observational inception study. Arthritis Rheum 2003;48:46-53.
29. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis-an approach to understanding the molecular-genetics of susceptibility to rheumatoid-arthritis. Arthritis Rheum 1987;30:1205-13.
30. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T-Cell in initiating and maintaining the chronic synovitis of rheumatoid-arthritis. Arthritis Rheum 1992;35:729-35.
31. Matthews N, Emery P, Pilling D, et al. Rheumatoid synovial T-Cell dysfunction can be explained by low Cd45rb expression. Arthritis Rheum 1992;35:S224.
32. Matthews N, Emery P, Pilling D, et al. Subpopulations of Primed-T Helper-Cells in Rheumatoid-Arthritis. Arthritis Rheum 1993;36:603-7.
33. Winchester R. The molecular-basis of susceptibility to rheumatoid-arthritis. Adv Immunol 1994:389-466.
34. Salmon M, Gaston J. The role of lymphocytes in rheumatoid arthritis. Br Med Bull 1995;51:332-45.
35. Panayi GS, Choy EHS, Connolly DJA, et al. T cell hypothesis in rheumatoid arthritis (RA) tested by humanised non-depleting anti-CD4 monoclonal antibody (mAb) treatment. 1. Suppression of disease activity and acute phase response. Immunology 1996;89:379.
36. Verburg R, Flierman R, Sont J, et al. Outcome of intensive immunosuppression and autologous stemcell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration. Ann Rheum Dis 2005;64:1397-405.